✨ Free AI Report
Renalytix Plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Renalytix Plc
Company Research

Renalytix Plc: Business Overview, Financials & Competitive Analysis

Renalytix Plc scores 4/10 on the AskCyborg Cyborg Score (Mixed). High-potential AI diagnostics platform with strong regulatory positioning, but challenged by slow commercial adoption and capital intensity in a competitive market. The company has achieved important regulatory milestones (FDA authorization) and strategic partnerships, but faces significant commercialization challenges evidenced by stock price decline from 1,220 GBX (June 2021) to 5.90.

What is Renalytix Plc's industry? Renalytix Plc (renalytix.com) operates in AI-Enabled In Vitro Diagnostics and Laboratory Services. AskCyborg classifies Renalytix Plc under AI-Enabled In Vitro Diagnostics and Laboratory Services in its company registry.

Renalytix is an AI-enabled in vitro diagnostics company focused on kidney disease management. The company's flagship product, KidneyIntelX, uses artificial intelligence, blood-based biomarkers, genetics, and patient h...

4/ 10Mixed

Cyborg Score thesis

High-potential AI diagnostics platform with strong regulatory positioning, but challenged by slow commercial adoption and capital...

Read the full analyst-debate transcript →
Industry AI-Enabled In Vitro Diagnostics and Laboratory Services
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Renalytix Plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Renalytix Plc

AskCyborg analysts argue the bull and bear cases for Renalytix Plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Renalytix Plc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Renalytix Plc Overview

Pro stress-test →

Renalytix is an AI-enabled in vitro diagnostics company focused on kidney disease management. The company's flagship product, KidneyIntelX, uses artificial intelligence, blood-based biomarkers, genetics, and patient health data to predict rapid kidney function decline in patients with type 2 diabetes and chronic kidney disease.

Strategic Profile

Pro stress-test →

Renalytix is the global founder and leader in bioprognosis for kidney health, holding FDA authorization for its KidneyIntelX test with broad insurance coverage. The company leverages strategic partnerships with major pharmaceutical companies like AstraZeneca and healthcare systems to expand adoption and clinical validation of its prognostic platform.

Competitive Landscape

Pro stress-test →

Renalytix operates in the AI-enabled diagnostics space competing against traditional diagnostic providers and emerging AI health tech companies. The company's niche focus on kidney disease prognosis provides differentiation, though it faces broader competition from large diagnostic lab services (LabCorp, Quest Diagnostics) and specialized kidney health platforms. Market adoption depends on physician education and demonstrated clinical outcomes value.

Industry Context

Renalytix Plc operates in AI-Enabled In Vitro Diagnostics and Laboratory Services.

Key facts

Founded: 2018 · Headquarters: London, UK · Employees: 46 · Revenue: Unknown · Market cap: Unknown

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Renalytix Plc.

  • KidneyIntelX has FDA authorization and broad insurance coverage, including Medicare reimbursement at $950 per test, establishing commercial legitimacy
  • Strategic collaborations with AstraZeneca and Mount Sinai Health System provide partnership validation and potential revenue diversification beyond direct testing
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2023Appointed Howard Doran as Chief Business Officer to lead global KidneyIntelX sales efforts
  • May 2024Reported Q3 FY2024 financial results with continued focus on test adoption and clinical validation
  • +1 moreTrack every material event for Renalytix Plc as it happens. Explore monitoring →
Get alerted when Renalytix Plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Kidney Disease DiagnosticsTraditional lab diagnostics with broad menu including kidney function tests→AI Health AnalyticsBroad-based AI diagnostic platforms competing in precision health space→

Compare Renalytix Plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Renalytix Plc operates in AI-Enabled In Vitro Diagnostics and Laboratory Services. See how the rest of the sector scores on the Cyborg framework.

Browse AI-Enabled In Vitro Diagnostics and Laboratory Services research →
NEW · MCP server

Ask your AI assistant about Renalytix Plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Renalytix Plc and its top competitor on Cyborg Score”
“What did Renalytix Plc do this quarter?”
“Is Renalytix Plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Renalytix Plc do?+
Renalytix is an AI-enabled in vitro diagnostics company focused on kidney disease management. The company's flagship product, KidneyIntelX, uses artificial intelligence, blood-based biomarkers, genetics, and patient h...
What is Renalytix Plc's Cyborg Score?+
Renalytix Plc has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Renalytix Plc's main competitors?+
Named competitors include Kidney Disease Diagnostics, AI Health Analytics. The full competitive landscape is in the AskCyborg report.
How can I get the full Renalytix Plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Renalytix Plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Renalytix Plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.